Recent meta-analyses have shown that in adults with possible tuberculosis, with or without HIV infection, the assay is sensitive and specific and substantially increases tuberculosis detection compared with smear microscopy [10] .
The lateral flow urine lipoarabinomannan assay (Determine tuberculosis lipoarabinomannan(TB LAM) assay), another recent POC test, detects lipoarabinomannan, a lipopolysaccharide present in mycobacterial cell walls, in persons with active tuberculosis disease [11] . The WHO identifies the LAM assay as a usable tool to assist in diagnosing tuberculosis in HIV-positive patients who have signs and symptoms of tuberculosis (pulmonary and/ or extrapulmonary) or are seriously ill [12] . Although this assay has lower sensitivity than other methods for detecting tuberculosis in adults with HIV, its use in combination with other tests may increase the diagnostic rate in HIV-positive individuals, particularly in those with low CD4 cell counts [11] .
The combination of LAM and sputum Xpert assays (along with clinical signs) was associated with a 13% increase in sensitivity over the Xpert assay alone [13] . To define optimal diagnostic algorithms for tuberculosis among persons with HIV, we defined a study protocol based on combined diagnostic testing of sputum (Xpert) and urine (LAM) samples from all HIVinfected persons eligible for antiretroviral therapy (ART). The main objectives of the study were to define the local prevalence of tuberculosis disease (using WHO-endorsed molecular testing that also assess rifampicin resistance) among ART-naive HIVpositive subjects, the prevalence of subclinical disease in patients positive for tuberculosis (using WHO-defined symptoms), and the added values of including in diagnostic algorithms for tuberculosis a repeated Xpert sputum test and a urine LAM test.
METHODS
The study was conducted within the Disease Relief through Excellent and Advanced Means (DREAM) program of the Community of S. Egidio, an Italian faith-based nongovernmental organization. The study protocol was approved by the National Committee for Health Bioethics of the Mozambican Ministry of Health (36; ref. no. CNBS/2014). All participants provided informed consent. The study included all HIV-positive patients >15 years old followed up in the DREAM health centers of Maputo, Machava and Beira (Mozambique) and prescribed ART; patients were screened for tuberculosis before starting ART, with a combined approach that included WHO 4-symptom screening (WHO-4SS; symptoms included fever, current cough, night sweats, and weight loss) [14] , a rapid test for detection of mycobacterial lipoarabinomannan in urine (Determine TB LAM assay; Alere), and a molecular tuberculosis assay performed on sputum samples (Xpert MTB/RIF Assay system; Cepheid), which was repeated if the first result was negative.
Demographic and clinical information was collected during routine clinical visits at the DREAM health centers. Participants provided 1 or 2 respiratory sputum samples (with a second sample collected 2 or 3 days later only if the first result was negative), which were tested within 48 hours using the Xpert MTB/ RIF Assay system, and 1 urine sample, which was tested within 1 hour using the Determine TB LAM assay; both assays were performed according to manufacturer's instructions. Detection of M. tuberculosis was carried out using a 4-module (G4) GeneXpert Dx System, with Xpert MTB/RIF Assay, version 5, and GeneXpert Dx System software, version 4.4a (Cepheid). Xpert testing was performed at Maputo (for the Maputo and Machava centers) and Beira.
Patients with either positive Xpert or positive LAM test results were considered tuberculosis infected and were referred for tuberculosis treatment, usually first-line treatment with a 4-drug fixed drug combination (150-mg rifampicin, 75-mg isoniazid, 400-mg pyrazinamide, and 275-mg ethambutol, once a day administration), with an individually defined second-line treatment when rifampicin resistance was detected with the Xpert assay. All patients were prescribed a combination of tenofovir, lamivudine, and efavirenz, unless clinically contraindicated. Population characteristics were summarized as medians with interquartile ranges (IQRs). Qualitative variables were compared using χ 2 or Fisher tests, and quantitative variables using the Mann-Whitney U test. Differences were considered statistically significant at P < .05. All analyses were performed using SPSS software, version 22 (IBM).
RESULTS
The study enrollment started in September 2014 and ended in October 2016. Overall, 1015 patients entered the study. Four of them were not eligible because of ongoing treatment for tuberculosis at enrollment (n = 2) or previous ART (n = 2). Thirty-nine additional patients were excluded because did not complete the protocol-defined tuberculosis diagnostic proce- Table 1 . Overall, 98 patients (10.1%) tested positive with either Xpert (n = 90; 9.3%) or LAM (n = 34; 3.5%) assays. Patients who tested positive for tuberculosis were more commonly male, older, and from the clinical site of Beira and showed significantly worse clinical and laboratory parameters, including lower CD4 cell counts and hemoglobin levels, higher plasma HIV RNA levels, and more advanced HIV WHO clinical stage.
At symptom screening with WHO-4SS, 334 patients (34.4%) were positive for ≥1 symptom, with 76 of them (22.8%) positive at either Xpert or LAM testing. Among the 98 patients with positive results of either Xpert or LAM tests, 22 (22.4%) had negative symptom screening results with WHO-4SS. Patients who had ≥1 WHO symptom had significantly lower CD4 cell counts (median, 187/μL; IQR, 82-335/μL) than those with no WHO-4SS symptoms (318/μL; 183.75-418/μL; P < .001). In the entire study population, the overall prevalence of tuberculosis among house contacts was 3.4%, with no significant differences between groups ( Table 1) .
The first Xpert test was positive in 74 of 972 patients (7.6%), and the second Xpert test, performed in the 898 patients with negative results at the first test, identified 16 additional patients, corresponding to 1.8% of those retested after initial negative results. Among 81 Xpert-positive patients with determinable resistance information, 2 (2.5%) had rifampicin resistance.
Concordance between Xpert and LAM test results was low. Among 74 patients with a first positive Xpert result, 24 (32.4%) were concomitantly positive at LAM testing. Among the Xpertpositive patients, LAM-positive patients had significantly lower CD4 cell counts than LAM-negative patients (median, 75/μL vs 149.5/μL; P = .003). Overall, LAM-positive patients (n = 33) had significantly lower CD4 cell counts (median 67/μL; IQR, 30-177/μL) than LAM-negative patients (n = 938; 282.5/μL; 149.75-399/μL, P < .001). Very few patients who tested negative with the Xpert assay were LAM positive: among 898 patients with a first negative Xpert result, only 10 (1.1%) were LAM positive, and 2 of them had a positive Xpert result when retested, corresponding to 8 patients who were LAM positive only in the entire study (0.8% with a dual-test Xpert strategy) ( Table 2) .
Fifteen of the 98 patients with positive Xpert or LAM test results did not start treatment for tuberculosis (5 dropped out, 3 transferred [a changed health center or a changed residence], 2 received no treatment owing to a clinician's decision, and 5 died). Among the remaining 83 patients who started treatment for tuberculosis, the median interval between start of the diagnostic algorithm (date of first Xpert test) and the start of tuberculosis treatment was 7 days (IQR, 4-9 days; range, 0-52 days). The median interval from tuberculosis diagnosis to the start of treatment was 6 days (IQR, 3-8 days; range, 0-52 days).
Overall, 24 patients who completed the tuberculosis diagnostics (13 with positive Xpert and/or LAM results) did not start ART, for the following reasons: 4 transferred (2 tuberculosis positive), 2 refused ART (0 tuberculosis positive), 10 dropped out (4 tuberculosis positive), and 8 died (7 tuberculosis positive). The remaining 948 patients started a 3-drug combination regimen, most commonly tenofovir, lamivudine, and efavirenz (n = 878; 92.6%) and less commonly zidovudine, lamivudine, and efavirenz (n = 29; 3.1%), zidovudine, lamivudine, and nevirapine (n = 28; 3.0%), or other regimens (n = 13; 1.4%). The median interval between completion of the tuberculosis diagnostic algorithm and the start of ART for the entire population was 6 days (IQR, 3-10 days), with a significant longer interval among tuberculosis-positive compared with tuberculosis-negative subjects (median, 21 vs 5 days, respectively; IQR, 14-29 vs 3-8 days; P < .001).
Patients followed up in Beira were significantly more likely to have positive test results for tuberculosis (prevalence, 24.0%, vs 6.2% in Maputo and 8.0% in Machava; P < .001 for both comparisons), had a lower median CD4 cell count (182/μL, vs 308/ μL in Maputo and 283/μL in Machava; both P < .001), and more advanced WHO HIV clinical stage (only 33.3% WHO stage I in Beira, vs 63.0% in Maputo and 84.1% in Machava; both P < .001). Patients from Beira were also more commonly male (51.5% vs 39.5% in Maputo [P = .009] and 39.1% in Machava [.006]), with no differences in median age (34 vs 35 and 36 years, respectively; P >.05 for both comparisons).
DISCUSSION
With the current WHO approach, based on administration of ART to all HIV-infected individuals, irrespective of CD4 cell count, ART can be started immediately after HIV testing in HIVpositive individuals, but it is critical to define their tuberculosis status, because tuberculosis may have severe consequences in terms of morbidity and mortality rates. In low-or medium-income countries, symptom screening is often used, but a significant proportion of patients with tuberculosis may be symptom negative and therefore be missed by simple symptom screening [15] . Identification of tuberculosis in culture requires time and resources, and even simpler approaches based on chest radiography or identification of acid-fast bacilli in sputum, although more rapid, may be operationally problematic. Implementation of rapid and reliable tests is therefore essential for an adequate diagnosis and treatment of tuberculosis in subjects with HIV.
Within this context, we evaluated a "reinforced" WHOendorsed approach, in which a first Xpert test was accompanied by a urine LAM test and an additional Xpert test, when the result of the first Xpert test was negative. With this approach, we observed a 10.1% prevalence of tuberculosis in an unselected population of HIV-infected individuals starting ART. In similar studies conducted in Africa, the prevalence of cultured M. tuberculosis from sputum in HIV-infected individuals at the start of ART was slightly higher (17%-18%) [15] [16] [17] , whereas in selected samples from other African countries, the prevalence was similar or even lower (13% in a large Ugandan HIV clinic [18] , 6% in Ethiopian symptomatic patients mostly receiving ART [19] , and 2.4% in pregnant women from Kenya [20] ).
In our study, prevalence showed marked geographic differences, with a 24% prevalence in Beira (the second-largest town, located in central Mozambique), compared with 6.2% in the capital Maputo and 8.0% in the smaller town of Machava, both in Southern Mozambique. The higher prevalence in Beira was not due to case selection, because all patients eligible for ART were included in the study, and it might therefore indicate higher local circulation of the disease in the population. Patients from Beira were in a more advanced disease stage, had lower CD4 cell counts, and were more frequently male. All these conditions increase the risk of tuberculosis in individuals with HIV [21] [22] [23] and may have represented additional cofactors. Mozambique is among the 22 high-burden countries for tuberculosis [24] , and distinct characteristics of the tuberculosis epidemics in the Beira district have already been described [25] . Particular attention should be directed toward the tuberculosis epidemics in this district, where prevalence and disease burden among individuals with HIV seem to be greater.
Rifampicin resistance, based on the results of the Xpert test, was relatively rare (2.5%). Previous studies had shown high rates of drug resistance in Mozambique; in samples sent for drug susceptibility testing, mostly from pretreated subjects, rates as high as 58.3% were reported [26, 27] . In subjects with no previous tuberculosis treatment, resistance was usually less frequent: 2 studies from the same region had shown rifampicin resistance in 5%-6% of the samples analyzed [28, 29] . The present findings, therefore, showing a 2.5% resistance rate to rifampicin, can be considered reassuring.
The prevalence of tuberculosis among house contacts was low (3.4%) and strictly consistent with data from a large systematic review, which showed a 3.1% prevalence of active tuberculosis among household contacts [30] . Patients with tuberculosis showed significant differences from tuberculosis-negative patients for some characteristics, which generally represent already well-described tuberculosis predictors: male sex, older age, more advanced HIV disease, and lower CD4 cell count and hemoglobin levels [21, 23, 31, 32] . The concurrence of tuberculosis with advanced HIV disease and the high mortality rate in the few days after enrollment suggest that an earlier diagnosis of HIV and tuberculosis could prevent significant disease and death. In general, the interval from tuberculosis diagnosis to the start of tuberculosis treatment was short (median, 6 days), but several patients did not start treatment, mostly owing to transfer, dropout or rapidly deteriorating clinical conditions. This situation represents an important operational challenge [28, 33] . The current study provided information on the additional value in tuberculosis case finding of adding a repeated Xpert test and a urinary LAM test to a single Xpert test. The second Xpert test identified as tuberculosis positive 16 additional patients with initially negative Xpert results (17.8% of all Xpert-positive cases and 16.3% of all tuberculosis cases detected), improving case finding by 21.6% compared with a single-test Xpert strategy. This is fully consistent with the 20% increase in sensitivity produced by a second sampling in children [34] and with the 22.9% increase reported in adults when a dual-test Xpert strategy was used [16] . Similarly, LAM testing identified 10 additional patients with negative at the first Xpert test (10.2% of all tuberculosis cases detected), and 8 patients with negative results at 2 consecutive Xpert tests (8.1% of all tuberculosis cases detected), improving case finding by 13.5% compared with a single-test and by 8.9% compared with a dual-test Xpert strategy. Such figures are consistent with the incremental diagnostic yield of 13.4% compared with Xpert testing and clinical signs only, reported in hospitalized or severely ill HIV-infected individuals from Kenya [13] .
Overall, the combined addition of a LAM test and a second Xpert test enabled identification of 24 additional cases (24.5% of all tuberculosis cases detected), improving case finding by 32.4% compared with a single-test Xpert strategy. This represents a significant advantage, which should be weighed against the additional costs of the procedures. The transfer of this strategy to any clinical setting and all economic evaluations, however, needs to take into account that tuberculosis case finding per se does not necessarily translates into clinical benefits, if tuberculosis treatment is not effectively implemented. In this study, 15% of tuberculosis cases did not receive tuberculosis treatment, confirming that a significant proportion of the patients with tuberculosis diagnosed do not start treatment [28, 33] . Efforts should be directed to prevent this occurrence, reducing as much as possible logistical difficulties and barriers to treatment, and preventing through earlier testing the presentation of patients with extremely advanced disease and very poor clinical conditions, significant predictors of both death and attrition [35] .
The data support the evaluation of tuberculosis in all HIVpositive patients at presentation, irrespective of symptoms: a symptom-based screening is likely to miss a significant proportion of tuberculosis cases, as already reported [16, 20] , with important clinical consequences for patients with undiagnosed tuberculosis, who are likely to present at a later stage, when treatment response is lower and mortality rates higher [35] . The persisting reliance on symptoms is documented by a few cases in which clinicians decided not to start tuberculosis treatment despite a positive test result (LAM or Xpert positive in 1 patient each) because patients were asymptomatic and in good general condition. This occurrence clearly underlines the difficulties associated with the introduction of rapid laboratory tests as the only diagnostic tools in a setting where empirical treatment based on clinical evaluation only had been widely used [36, 37] .
The external validity of the study is provided by a population-based recruitment that included all the HIV-infected individuals eligible for ART (unselected group). This study did not evaluate the presence of tuberculosis using conventional tests such as radiography, sputum microscopy, and sputum culture, but LAM and Xpert tests have been evaluated extensively in comparison with such diagnostic techniques [11, 34, [38] [39] [40] . Moreover, although the Xpert test has been already validated and endorsed for tuberculosis diagnosis, with widespread use in several African countries, information on its field application was still limited, and the current study contributed information that may be useful in implementing screening programs in similar settings.
In summary, using a combined diagnostic approach based on rapid POC tests, we showed a 10% prevalence of undiagnosed tuberculosis in a large and unselected series of HIV-infected Mozambican individuals starting ART, with a significant added diagnostic value of repeated Xpert testing and LAM urinary testing. Symptom screening was only partially effective in identifying tuberculosis-positive patients. The diagnostic algorithm confirmed the feasibility of a rapid tuberculosis diagnostic process in the field, but roughly 15% of patients with tuberculosis diagnosed did not receive tuberculosis treatment because of very severe disease or for logistical reasons. Further research and interventions are needed to remove logistical barriers to tuberculosis treatment and prevent presentation of patients with very advanced HIV/tuberculosis disease. 
